PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION

For prevention of thromboembolic events in patients with non-valvular atrial fibrillation (NVAF) the following types of antithrombotic therapy are used: anticoagulant therapy with vitamin K antagonists (warfarin), antiplatelet therapy (acetylsalicylic acid) and novel oral anticoagulants such as apix...

Descrición completa

Gardado en:
Detalles Bibliográficos
Autor Principal: A. V. Rudakova
Formato: Artigo
Idioma:Inglês
Publicado: Stolichnaya Izdatelskaya Kompaniya 2015-09-01
Series:Racionalʹnaâ Farmakoterapiâ v Kardiologii
Assuntos:
atrial fibrillation
novel oral anticoagulants
cost-effectiveness analysis
apixaban
rivaroxaban
dabigatran
warfarin
aspirin
Acceso en liña:https://www.rpcardio.com/jour/article/view/61
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares